CompletedPhase 2NCT01625520
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
Studying Medullary thyroid carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Federico II University
- Principal Investigator
- Annamaria Colao"Federico II" University of Naples, Italy
- Intervention
- SOM230 alone or in combination with RAD001.(drug)
- Enrollment
- 19 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2012
Study locations (1)
- Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University of Naples, Naples, Italy, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01625520 on ClinicalTrials.govOther trials for Medullary thyroid carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07383246CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTCCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGNCT07142005Cultural Adaptation of an Educational Tool in Medullary Thyroid CancerM.D. Anderson Cancer Center
- RECRUITINGNANCT07138716Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTCLuo Yaping
- ENROLLING BY INVITATIONNCT06852144PET-TC in Thyroid EvaluationIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNANCT06141369Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)Shanghai Jiao Tong University School of Medicine
- RECRUITINGNANCT0627718068Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTCCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE1NCT06520319Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid CarcinomaFirst Affiliated Hospital of Fujian Medical University
- RECRUITINGPHASE4NCT05830500Study of Anlotinib in Patients With Advanced Medullary Thyroid CarcinomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.